<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Mice lacking <z:chebi fb="70" ids="18291,35154">manganese</z:chebi>-<z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase (Mn-SOD) activity exhibit typical pathology of <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo> (<z:chebi fb="20" ids="15767">DCM</z:chebi>) </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study, the structure-activity relationship between the water-soluble <z:chebi fb="70" ids="18291,35154">manganese</z:chebi> (Mn) <z:chebi fb="2" ids="8337">porphyrin</z:chebi> with SOD activity and the in vivo pharmaceutical effect on <z:chebi fb="20" ids="15767">DCM</z:chebi> is reported </plain></SENT>
<SENT sid="2" pm="."><plain>The Mn-SOD-deficient mice were treated with Mn-<z:chebi fb="2" ids="8337">porphyrins</z:chebi> for 3 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>The treatment of a Mn-<z:chebi fb="2" ids="8337">porphyrin</z:chebi>, MnM2Py(2)P, suppressed the progression of cardiac dilation </plain></SENT>
<SENT sid="4" pm="."><plain>These results suggest that the Mn-<z:chebi fb="2" ids="8337">porphyrin</z:chebi> MnM2Py(2)P treatment is proposed as a potential therapy for <z:chebi fb="20" ids="15767">DCM</z:chebi> </plain></SENT>
</text></document>